QUINN ROBERT E 4
4 · CANDELA CORP /DE/ · Filed Feb 3, 2010
Insider Transaction Report
Form 4
QUINN ROBERT E
Corporate Controller/Treasurer
Transactions
- Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−20,000→ 0 totalExercise: $15.33Exp: 2016-01-30→ Common Stock, $0.01 par value per share (20,000 underlying) - Disposition to Issuer
Common Stock
2010-01-05−50,000→ 0 total - Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−20,000→ 0 totalExercise: $4.29Exp: 2018-01-25→ Common Stock, $0.01 par value per share (20,000 underlying) - Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−21,639→ 0 totalExercise: $0.41Exp: 2019-01-19→ Common Stock, $0.01 par value per share (21,639 underlying) - Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−25,000→ 0 totalExercise: $11.53Exp: 2017-04-03→ Common Stock, $0.01 par value per share (25,000 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2010-01-05−10,000→ 0 totalExercise: $6.56Exp: 2013-08-11→ Common Stock, $0.01 par value per share (10,000 underlying)
Footnotes (6)
- [F1]These shares were disposed of pursuant to a merger agreement between the Issuer and Syneron Medical Ltd. ("Syneron") in exchange for 14,555 ordinary shares of Syneron having a market value of $10.39 per share at the close of trading on the effective date of the merger.
- [F2]The stock-settled stock appreciation rights, which were exercisable in two equal installments beginning on January 19, 2010, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 6,299 ordinary shares of Syneron at an exercise price of $1.41 per share.
- [F3]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on January 25, 2009, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 5,822 ordinary shares of Syneron at an exercise price of $14.74 per share.
- [F4]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on January 30, 2007, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 5,822 ordinary shares of Syneron at an exercise price of $52.67 per share.
- [F5]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on April 3, 2008, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 7,277 ordinary shares of Syneron at an exercise price of $39.61 per share.
- [F6]The incentive stock options, which were exercisable in one installment beginning on August 11, 2004, were vested in full and assumed by Syneron as a result of the merger and replaced with incentive stock options to purchase 2,911 ordinary shares of Syneron at an exercise price of $22.55 per share.